Most Popular
-
1
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
2
S. Korea not to attend Sado mine memorial: foreign ministry
-
3
First snow to fall in Seoul on Wednesday
-
4
Wealthy parents ditch Korean passports to get kids into international school
-
5
Man convicted after binge eating to avoid military service
-
6
Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
-
7
[Weekender] Korea's traditional sauce culture gains global recognition
![[Weekender] Korea's traditional sauce culture gains global recognition](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
-
8
BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
-
9
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
10
Nvidia CEO signals Samsung’s imminent shipment of AI chips
![[Weekender] Korea's traditional sauce culture gains global recognition](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
Mundipharma partners with Samsung Bioepis for Hong Kong, Taiwan
By Korea HeraldPublished : Jan. 13, 2020 - 16:14
UK-based Mundipharma said Monday it has secured a partnership with Korea’s Samsung Bioepis to commercialize its first-wave biosimilar candidates in Taiwan and Hong Kong.
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab) and SB8 (bevacizumab).
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab) and SB8 (bevacizumab).
Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain responsible for clinical development, regulatory registration and manufacture of the biosimilars.
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO Raman Singh in a statement. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments.”
(khnews@heraldcorp.com)
-
Articles by Korea Herald
![[More than APT] Residents, architects together design homes](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/11/24/20241124050036_0.jpg&u=)
